Changes in the Level of Antiphospholipid Antibodies (Anticardiolipin and Anti-β2-Glycoprotein-I) and Thromboembolic Indices in COVID-19 Patients during 3 Weeks.
Anticardiolipin
COVID-19
anti-β2-glycoprotein-I
thrombosis
Journal
International journal of preventive medicine
ISSN: 2008-7802
Titre abrégé: Int J Prev Med
Pays: Iran
ID NLM: 101535380
Informations de publication
Date de publication:
2023
2023
Historique:
received:
25
08
2021
accepted:
27
10
2022
medline:
23
6
2023
pubmed:
23
6
2023
entrez:
23
6
2023
Statut:
epublish
Résumé
COVID-19 is a respiratory disease caused by infection with severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). Thrombotic complications appear to be of particular importance in patients with COVID-19. This study aimed to investigate Changes in the level of Antiphospholipid antibodies (Anticardiolipin and Anti-β2-glycoprotein-I) and thromboembolic indices in COVID-19 patients during 3 weeks. This cross-sectional study was performed on adults with Covid-19 hospitalized at Al-Zahra Hospital in Isfahan. The case group includes the patients admitted to the internal ward or ICU who despite receiving prophylactic or anticoagulant doses suffer from thrombotic complications and the control group includes COVID-19 patients without thromboembolic events. The sample size of 120 people was considered. Anticardiolipin and anti-β2-glycoprotein-I antibodies, coagulation profiles including Fibrinogen, PTT, PT Troponin, ESR, CRP, and D-dimer were examined. After collection, the data were entered into spss24 software and analyzed. The results showed that there was no statistically significant difference in the changes of anticardiolipin and anti-beta-2 glycoprotein in IgM and IgG as well as in the changes of ESR, CRP, PTT, PT, and fibrinogen in the two groups ( Our study showed that there was no statistically significant relationship between anti-phospholipid antibodies (anticardiolipin and anti-beta-2 glycoprotein) and thromboembolic events. Therefore anticardiolipin and anti-beta-2 glycoprotein is probably the puzzles causing thrombosis in COVID-19 patients, and other inflammatory responses should be examined among the cases.
Identifiants
pubmed: 37351036
doi: 10.4103/ijpvm.ijpvm_377_21
pii: IJPVM-14-38
pmc: PMC10284197
doi:
Types de publication
Journal Article
Langues
eng
Pagination
38Informations de copyright
Copyright: © 2023 International Journal of Preventive Medicine.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
J Thromb Thrombolysis. 2021 Aug;52(2):542-552
pubmed: 33973157
Autoimmun Rev. 2021 Feb;20(2):102729
pubmed: 33321245
J Thromb Haemost. 2020 Jun;18(6):1421-1424
pubmed: 32271988
Thromb Res. 2020 Jul;191:148-150
pubmed: 32381264
N Engl J Med. 2018 May 24;378(21):2010-2021
pubmed: 29791828
J Am Coll Cardiol. 2020 May 12;75(18):2352-2371
pubmed: 32201335
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
Radiology. 2020 Sep;296(3):E189-E191
pubmed: 32324102
Rheumatol Int. 2021 Jul;41(7):1243-1252
pubmed: 33954813
J Immunol. 2015 Feb 1;194(3):855-60
pubmed: 25596299
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32245835
Circulation. 2020 Jul 14;142(2):184-186
pubmed: 32330083
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Front Immunol. 2020 Oct 15;11:584241
pubmed: 33178218
Thromb Res. 2020 Aug;192:113-115
pubmed: 32425261
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Crit Care. 2020 Jun 18;24(1):360
pubmed: 32552865
J Thromb Haemost. 2020 Sep;18(9):E3-E4
pubmed: 32608109
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
Glob Health Res Policy. 2020 Mar 2;5:6
pubmed: 32226823
N Engl J Med. 2020 Apr 23;382(17):e38
pubmed: 32268022
Arthritis Rheumatol. 2021 May;73(5):897-899
pubmed: 33381888